The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE

The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE that works at an advanced clinical stage on the treatment of neurodegenerative diseases.

REGEnLIFE and IGHS settled a strategic partnership to anticipate future developments related with the mission of the French company, offering innovative technologies that will improve the health and everyday lives of patients with debilitating neurological conditions such as Alzheimer's disease. 

REGEnLife has as Chief Medical Officer and Chairman of the Scientific Advisory Board the Professor Jacques Touchon, former Dean of the Montpellier School of Medicine and International Key Opinion Leader on Alzheimer’s disease, that was present in Oman.

• Expanding successful business relationships in Middle-East

  Creating solid business alliances in the Middle-East region bridges new exciting paths for Innov-Cell Therapeutics, a subsidiary of the IGHS group.

  Read more
• The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE

  The IGHS Group welcomed, at the Oman International Hospital, the neurotech company REGEnLIFE that works at an advanced clinical stage on the treatment of neurodegenerative diseases.

  Read more